OSAI
Membranous nephropathy : a model for solving organ-specific auto-immunity (OSAI)
| Coordinatore | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 2˙500˙000 € |
| EC contributo | 2˙500˙000 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2012-ADG_20120314 |
| Funding Scheme | ERC-AG |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-05-01 - 2018-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | hostInstitution | 2˙500˙000.00 |
| 2 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | hostInstitution | 2˙500˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Membranous nephropathy (MN) is a paradigm of organ-specific autoimmune disease which affects the kidney glomerulus, resulting in the formation of immune deposits, complement-mediated proteinuria, and renal failure. My group has recently identified 2 causative antigens (neutral endopeptidase and bovine serum albumin) in children, and 2 predisposing genes HLA-DQA1 and PLA2R1 coding for another antigen in adult MN. However, MN is most likely more complex, involving several antigen-antibody systems and immune response genes. To get a comprehensive view of self and food/environmental antigenic targets and of HLA and non-HLA trigger genes, and to design new rapidly acting therapies, I will develop novel technological approaches such as immunopeptidomics, and explore new pathophysiological and therapeutic concepts with 3 major objectives: 1. Identify the immune response targets (epitopes) using unbiased approaches such as HLA-class II peptidomics, random peptide libraries, and sequencing of candidate genes starting with PLA2R1 2. Investigate trigger genes by next generation sequencing (NGS) of the HLA-D locus and of other genes involved in autoimmunity and disease progression, in 150 pairs of donors and recipients with or without recurrence of MN, a situation offering a unique opportunity to analyze effects of genetic background 3. Revisit complement-related innate immunity by NGS sequencing of 18 complement regulatory protein genes in search of variants which may account for disease heterogeneity, by blocking C5b-9 formation with recombinant factor H in 2 murine models of MN, and by searching for C5b-9 antagonists by high-throughput screening of chemical libraries in podocyte cell-based assays. Our project will provide new biomarkers that will be used to set up reliable tests for diagnosis, monitoring, and prediction of outcome and recurrence of MN. It will result in new therapies, improved monitoring and ontology, and better understanding of organ-specific autoimmunity.'